The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

• Katarina Uttervall ,

  * E-mail: katarina.uttervall@ki.se

  Affiliations Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden, Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden

  ⨯
• Adil D. Duru,

  Affiliation Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden

  ⨯
• Johan Lund,

  Affiliations Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden, Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden

  ⨯
• Johan Liwing,

  Affiliation Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden

  ⨯
• Gösta Gahrton,

  Affiliation Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden

  ⨯
• Erik Holmberg,

  Affiliation Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden

  ⨯
• Johan Aschan,

  Affiliation Janssen-Cilag AB, Sollentuna, Sweden

  ⨯
• Evren Alici,

  Affiliations Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden, Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden

  ⨯
• Hareth Nahi

  Affiliations Department of Medicine, Karolinska Institutet Huddinge, Stockholm, Sweden, Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden

  ⨯